Patents by Inventor Alan Paul Watt

Alan Paul Watt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS
    Publication number: 20230145050
    Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
    Type: Application
    Filed: October 17, 2022
    Publication date: May 11, 2023
    Inventors: David HARRISON, Alan Paul WATT, Mark G. BOCK
  • Sulphonyl urea derivatives as NLRP3 inflammasome modulators
    Patent number: 11518757
    Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: December 6, 2022
    Assignee: NodThera Limited
    Inventors: David Harrison, Alan Paul Watt, Mark G. Bock
  • Urea derivatives and methods of use thereof
    Patent number: 11345669
    Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein inhibit the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inter alia autoinflammatory and autoimmune diseases and cancers.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: May 31, 2022
    Assignee: NodThera Limited
    Inventors: David Harrison, Alan Paul Watt, Nicolas Boutard, Charles-Henry Fabritius, Michal Galezowski, Piotr Kowalczyk, Oleksandr Levenets, Jakub Woyciechowski
  • SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME
    Publication number: 20210087147
    Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and autoimmune diseases and cancers.
    Type: Application
    Filed: July 31, 2018
    Publication date: March 25, 2021
    Inventors: Mark G. BOCK, David HARRISON, Alan Paul WATT, Roderick Alan PORTER, Nicolas Felix Pierre BOUTARD, Charles-Henry Robert Yves FABRITIUS, Grzegorz Witold TOPOLNICKI, Oleksandr LEVENETS
  • SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS
    Publication number: 20210002261
    Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
    Type: Application
    Filed: December 18, 2018
    Publication date: January 7, 2021
    Inventors: David HARRISON, Alan Paul WATT, Mark G. BOCK
  • CHEMICAL COMPOUNDS
    Publication number: 20200131141
    Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein inhibit the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inter alia autoinflammatory and autoimmune diseases and cancers.
    Type: Application
    Filed: March 12, 2018
    Publication date: April 30, 2020
    Inventors: David HARRISON, Alan Paul WATT, Nicolas BOUTARD, Charles-Henry FABRITIUS, Michal GALEZOWSKI, Piotr KOWALCZYK, Oleksandr LEVENETS, Jakub WOYCIECHOWSKI
  • Amidine derivatives as selective antagonists of ndma receptors
    Publication number: 20030119871
    Abstract: A class of styryl amidine derivatives which are antagonists of the hum NMDA receptor, being selective for those containing the NR2B subunit, are active in the treatment and/or prevention of neurological and neurodegenerative disorders, in particular neuropathic pain and headache, specifically migraine, whils displaying fewer ataxic and related side-effects associated with other classes of NMDA receptor antagonists.
    Type: Application
    Filed: December 16, 2002
    Publication date: June 26, 2003
    Inventors: Neil Roy Curtis, Janusz Jozef Kulagowski, Steve Thomas, Alan Paul Watt